Geraldine Liot

Fontenay-sous-bois, 92265, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Loss of the neuronal kinase DCLK3 leads to anxiety-like behaviour and memory deficits.

Loss of the neuronal kinase DCLK3 leads to anxiety-like behaviour and memory deficits.

Journal: Brain : a journal of neurology

Published: May 02, 2024

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma.

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma.

Journal: Cell reports

Published: January 12, 2023

The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

Journal: International journal of molecular sciences

Published: April 27, 2021

Zero Echo Time 17O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis.

Zero Echo Time 17O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis.

Journal: Metabolites

Published: March 21, 2021

The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.

The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.

Journal: Neurobiology of disease

Published: March 12, 2019

The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Journal: The European journal of neuroscience

Published: May 13, 2018

The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin.

The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin.

Journal: Brain : a journal of neurology

Published: July 07, 2017

Energy defects in Huntington's disease: Why "in vivo" evidence matters.

Energy defects in Huntington's disease: Why "in vivo" evidence matters.

Journal: Biochemical and biophysical research communications

Published: September 08, 2016

Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14).

Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14).

Journal: Investigative ophthalmology & visual science

Published: April 21, 2016

Sulfheme formation during homocysteine S-oxygenation by catalase in cancers and neurodegenerative diseases.

Sulfheme formation during homocysteine S-oxygenation by catalase in cancers and neurodegenerative diseases.

Journal: Nature communications

Published: February 18, 2016

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.

Journal: Oncotarget

Published: October 06, 2015

Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.

Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.

Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience

Published: April 12, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026